TUESDAY, JUNE 1

Welcoming Remarks and Keynote Session (Joint) (7am Denver/Mountain Time Start)

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Accelerating HIV Vaccine Development to Prevent HIV Infection

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
I Am Nothing Without You: The Rationale for T Cell Plus B Cell Vaccines for HIV

Breakthrough Technologies (Joint) (8:10am Denver/Mountain Time Start)

Mark M. Davis, Stanford University School of Medicine, USA
Novel Tonsil Organoid Culture System

Guillaume J. Filion, University of Toronto Scarborough, Canada
What Have We Learned from HIV-Barcoding Technologies?

Short Talks Chosen from Abstracts

Insights from Preclinical and Clinical Trials (9:30am Denver/Mountain Time Start) (EK42)

Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
AMP Trial Results

Sandhya Vasan, US Military HIV Research Program, USA
Optimizing Adjuvants for Clinical Vaccine Development

William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Human Clinical Test of Germline Targeting: Preliminary Report on B-Cell Responses in the IAVI G001 Trial of eOD-GT8 60mer

Robin Shattock, Imperial College London, UK
Accelerated Experimental Medicine Trials for Iterative Vaccine Design

Short Talks Chosen from Abstracts

New Insights into HIV Virology (9:30am Denver/Mountain Time Start) (EK43)

Bryan R. Cullen, Duke University Medical Center, USA
Epitranscriptomic Regulation of HIV-1 RNA Stability and Alternative Splicing

Marina Lusic, University Clinic Heidelberg, Germany
Navigating through the Nucleus with HIV-1

Xu Yu, Massachusetts General Hospital, USA
Proviral Landscape of HIV-1 in Elite Controllers

Short Talks Chosen from Abstracts

Career Roundtable (Joint) (1pm Denver/Mountain Time Start)

Immunogen Design for Broadly Neutralizing Antibody Induction (7am Denver/Mountain Time Start) (EK42)

Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
Structural Details of Antibody Interactions with the HIV-1 Glycan Shield and Implications for Vaccine Design

Short Talks Chosen from Abstracts

New Insights into Restriction Factors (7am Denver/Mountain Time Start) (EK43)

Frank Kirchhoff, University of Ulm, Germany
Novel Restriction Factors Targeting HIV-1 Dependencies

Jeremy Luban, University of Massachusetts Medical School, USA
Primate Immunodeficiency Virus Proteins Vpx and Vpr Counteract Transcriptional Repression of Proviruses by the HUSH Complex

Reuben S. Harris, University of Minnesota, USA
Unexpected Discoveries from Attempting to Apply Lessons from HIV-1 to SARS-CoV-2

Short Talks Chosen from Abstracts

Inducing/Modulating Antibody Effector Functions (9:30am Denver/Mountain Time Start) (EK42)

Hugo Mouquet, Institut Pasteur, France
Broadly HIV-1 Neutralizing IgA Antibodies

Margaret E. Ackerman, Dartmouth College, USA
Optimizing Antibodies for Antiviral Activity in vivo

Rasmi Thomas, U.S. Military HIV Research Program, USA
Single Cell Technologies Indicate Monocyte Expression Profiles Influence HIV Reservoir Size and Vaccine Efficacy

Short Talks Chosen from Abstracts

LRAs and Immunomodulatory Agents (9:30am Denver/Mountain Time Start) (EK43)

Devi SenGupta, Gilead Sciences, Inc., USA
Immune-Based Strategies for HIV Cure

Jerome A. Zack, University of California, Los Angeles, USA
Controlling HIV Rebound in Humanized Mice

For the most up-to-date details, visit https://www.keystonesymposia.org.

* Session Chair † Invited but not yet accepted

Program current as of May 8, 2021.
Melanie M. Ott, Gladstone Institutes, USA
SMYD Methyltransferases are Versatile Regulators of HIV Transcription

Short Talks Chosen from Abstracts

Poster Session 1 (Joint) (1pm Denver/Mountain Time Start)

THURSDAY, JUNE 3

Optimizing Germinal Center Responses for Broadly Neutralizing Antibody Induction (7am Denver/Mountain Time Start) (EK42)

Facundo D. Batista, Massachusetts Institute of Technology and Harvard University, USA
Targeting HIV-1 ENV V2-apex bNAb Precursors in Human Ig Knock-in Mouse Models

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Designing Immunization Regimens to Promote the Germinal Center Response

Persephone Borrow, University of Oxford, UK
Exploiting the Immunological Environment Supporting HIV-1 BnAb Induction During Infection to Inform Vaccine Design

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
GC Regulation Learning from Mice and Men

Short Talks Chosen from Abstracts

New Insights into HIV Latency and Reservoirs (7am Denver/Mountain Time Start) (EK43)

Carine M. Van Lint, University of Brussels, Belgium
The Molecular Basis of HIV-1 Latency

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Understanding Viral Rebound

Maria J. Buzon, Vall d’Hebron Research Institute, VHIR, Spain
Characterization of the Active HIV Reservoir during ART

Angela Ciuffi, Institute of Microbiology - CHUV/UNIL, Switzerland
HIV and Single-Cell Analyses

Short Talks Chosen from Abstracts

CD8 T Cell Inducing Vaccines (9:30am Denver/Mountain Time Start) (EK42)

Louis J. Picker, Oregon Health & Science University, USA
Latest Developments in CMV-Vectored HIV/SIV Vaccines

Andrew J. McMichael, Oxford University, UK
Understanding HLA-E Mediated Antigen Presentation to Inform Vaccine Design

Bette Korber, Los Alamos National Laboratory, USA
Design of Vaccines to Elicit Conventional (la)-restricted CD8 T Cell Responses

Michael R. Betts, University of Pennsylvania, USA
CD8+ T Cell Tissue Recirculation and Residency in HIV Infection

Short Talks Chosen from Abstracts

Immunotherapy in Animal Models and Clinical Trials (9:30am Denver/Mountain Time Start) (EK43)

Sharon R. Lewin, University of Melbourne, Australia
Immune Checkpoint Blockers and HIV Cure Strategies

Steven G. Deeks, University of California, San Francisco, USA
Immunotherapy and HIV Control

Afaam Okoye, Oregon Health & Science University, USA
Evaluating Strategies for Post-ART Viral Control

Liang Shan, Washington University in St. Louis, USA
CARD8 Mediates Pyroptosis of HIV-Infected Cells by Sensing Viral Protease Activity

Short Talks Chosen from Abstracts

Therapeutic Vaccines (Joint) (7am Denver/Mountain Time Start)

Barbara K. Felber, NCI, National Institutes of Health, USA
Therapeutic Vaccines – Preclinical to Clinical Trials

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Therapeutic Antibody and Vaccine Strategies

Julie Ake, Walter Reed Army Institute of Research, USA
HIV Remission in Acutely Treated Populations

Brad Jones, Weill Cornell Medicine, USA
Target-Intrinsic CTL Resistance, A Role in Reservoir Persistence?

Beatriz Mothe, IrsiCaixa AIDS Research Institute-HIVACAT, Spain
AELIX-002: A RCT with HTI Therapeutic Vaccines in Early-Treated HIV

Short Talks Chosen from Abstracts

Considerations in Future Vaccine Design (9:30am Denver/Mountain Time Start) (EK42)

Keith Reeves, Duke University School of Medicine, USA
HIV-Specific NK Cells Responses and their Potential for Harnessing in Vaccine Design

Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory, South Africa
Innate Immune Signatures Associated with HIV Vaccine Immunogenicity

Nichole R. Klatt, University of Minnesota, USA
Potential Role of the Microbiome in HIV Vaccination

Short Talks Chosen from Abstracts

Immunotherapeutic and Gene Therapy Approaches Targeting the HIV Reservoirs (9:30am Denver/Mountain Time Start) (EK43)
Rafick Sekaly, Emory University, USA
A Novel T Cell Stem Cell Leads to HIV Control and HIV Persistence

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Gene Editing the Ig Locus of B Cells to Produce Single-Chain Antibodies against HIV

Petronela Ancuta, Centre de Recherche de l'Universite de Montreal, Canada
Targeting Th17 Cells in HIV Cure/Remission Strategies

Beatrice H. Hahn, University of Pennsylvania, USA
Type 1 Interferon Resistance of HIV-1 is Highest at Transmission and Following Treatment Interruption

Short Talks Chosen from Abstracts